<?xml version="1.0" encoding="UTF-8"?><html xmlns="http://www.w3.org/1999/xhtml" xmlns:oboInOwl="http://www.geneontology.org/formats/oboInOwl#" xmlns:NCBITaxon="http://purl.obolibrary.org/obo/NCBITaxon#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:obo="http://purl.obolibrary.org/obo/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:ncbitaxon="http://purl.obolibrary.org/obo/ncbitaxon#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#" xmlns:dublincorens="http://purl.org/dc/elements/1.1/"  version="XHTML+RDFa 1.0" ><body>                            NIH Public Access <br />                             Author Manuscript <br />                             Int J <span id='am-14' about='obo:NCBITaxon_6754' typeof='owl:Thing obo:NCBITaxon_33213 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_72041 obo:NCBITaxon_33154 obo:NCBITaxon_6681 obo:NCBITaxon_6682 obo:NCBITaxon_6683 obo:NCBITaxon_29964 obo:NCBITaxon_33317 obo:NCBITaxon_2759 obo:NCBITaxon_6072 obo:NCBITaxon_33208 obo:NCBITaxon_116706 obo:NCBITaxon_116704 obo:NCBITaxon_197562 obo:NCBITaxon_197563 obo:NCBITaxon_6656 obo:NCBITaxon_6692 obo:NCBITaxon_1206794 obo:NCBITaxon_6657 obo:NCBITaxon_6753 obo:NCBITaxon_88770 obo:NCBITaxon_6752'><span id='am-15' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-16'  ></span><span id='am-17' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-18' property="rdfs:label" content="Cancer" datatype="xsd:string"></span>Cancer</span>. Author manuscript; available PMC 2009 October 1. <br />                            Published final edited form as: <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                             Int J Cancer. 2008 October 1; 123(7): 1721&#8211;1725. doi:10.1002/ijc.23665. <br />  <br />  <br />  <br />                            The Mitotic Checkpoint Gene, SIL Regulated E2F1 <br />  <br />                            Ayelet Erez, MD,PhD1,2, Marie Chaussepied, PhD3,4, Colaizzo-<span id='am-24' about='obo:NCBITaxon_8835' typeof='owl:Thing obo:NCBITaxon_33213 obo:NCBITaxon_1329799 obo:NCBITaxon_1 obo:NCBITaxon_32523 obo:NCBITaxon_131567 obo:NCBITaxon_32524 obo:NCBITaxon_436489 obo:NCBITaxon_117570 obo:NCBITaxon_89593 obo:NCBITaxon_7742 obo:NCBITaxon_117571 obo:NCBITaxon_33154 obo:NCBITaxon_8782 obo:NCBITaxon_436486 obo:NCBITaxon_1338369 obo:NCBITaxon_8287 obo:NCBITaxon_2759 obo:NCBITaxon_8830 obo:NCBITaxon_8492 obo:NCBITaxon_6072 obo:NCBITaxon_33511 obo:NCBITaxon_33208 obo:NCBITaxon_8826 obo:NCBITaxon_7711 obo:NCBITaxon_8825 obo:NCBITaxon_7776 obo:NCBITaxon_436492 obo:NCBITaxon_32561 obo:NCBITaxon_8457 obo:NCBITaxon_436491'><span id='am-25' property="oboInOwl:hasExactSynonym" content="ducks" datatype="xsd:string"></span><span id='am-26' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-27' property="rdfs:label" content="Anas" datatype="xsd:string"></span><span id='am-28'  ></span><span id='am-29' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span>Anas</span> <span id='am-6' about='obo:NCBITaxon_557046' typeof='owl:Thing obo:NCBITaxon_78536 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_3398 obo:NCBITaxon_41937 obo:NCBITaxon_1437183 obo:NCBITaxon_33090 obo:NCBITaxon_91827 obo:NCBITaxon_131221 obo:NCBITaxon_71240 obo:NCBITaxon_58024 obo:NCBITaxon_91836 obo:NCBITaxon_1437201 obo:NCBITaxon_58023 obo:NCBITaxon_23672 obo:NCBITaxon_2759 obo:NCBITaxon_35493 obo:NCBITaxon_71275 obo:NCBITaxon_3193'><span id='am-7' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-8'  ></span><span id='am-9' property="rdfs:label" content="Tina" datatype="xsd:string"></span><span id='am-10' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span>Tina</span>, PhD5, Peter Aplan, <br />                            MD6, Doron Ginsberg, PhD7, Shai Izraeli, MD, MSc1,2 <br />                            1Department Pediatric Hemato-Oncology Sheba Cancer Research Center, Tel-Hashomer, Israel <br />                            2Sackler Faculty Medicine, Tel-Aviv University, Israel. <br />                            3Institute Cochin, Universite&#8217; <span id='am-34' about='obo:NCBITaxon_49669' typeof='owl:Thing obo:NCBITaxon_78536 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_50362 obo:NCBITaxon_4447 obo:NCBITaxon_3398 obo:NCBITaxon_1437183 obo:NCBITaxon_33090 obo:NCBITaxon_131221 obo:NCBITaxon_58024 obo:NCBITaxon_58023 obo:NCBITaxon_2759 obo:NCBITaxon_35493 obo:NCBITaxon_1437197 obo:NCBITaxon_4667 obo:NCBITaxon_3193'><span id='am-35' property="oboInOwl:hasRelatedSynonym" content="Paris L." datatype="xsd:string"></span><span id='am-36' property="rdfs:label" content="Paris" datatype="xsd:string"></span><span id='am-37' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-38'  ></span><span id='am-39' property="oboInOwl:hasAlternativeId" content="NCBITaxon:49665" datatype="xsd:string"></span><span id='am-40' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span>Paris</span> Descartes, CNRS (UMR 8104), Paris, France. <br />                            4Inserum, U567, Paris, France. <br />                            5Dietetics Nutrition Buffalo State-SUNY, Buffalo, NY14222. <br />                            6NIH/NCI/Genetics Branch, Bethesda, MD <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                            7The Mina &amp; Everard Goodman Faculty Life Sciences Bar Ilan University, Ramat gan, Israel <br />  <br />                            Abstract <br />                                 The SIL gene expression increased multiple cancers correlates expression mitotic <br />                                 spindle checkpoint genes increased metastatic potential. SIL regulates mitotic entry, <br />                                 organization mitotic spindle cell survival. The E2F transcription factors regulate cell cycle <br />                                 progression controlling expression genes mediating G1/S transition. More recently E2F <br />                                 shown regulate mitotic spindle checkpoint genes well. As SIL expression correlates <br />                                 mitotic checkpoint genes hypothesized SIL regulated E2F. We mined raw <span id='am-41' about='obo:NCBITaxon_1369087' typeof='obo:NCBITaxon_37567 owl:Thing obo:NCBITaxon_33340 obo:NCBITaxon_33213 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_85604 obo:NCBITaxon_104431 obo:NCBITaxon_33154 obo:NCBITaxon_37570 obo:NCBITaxon_41191 obo:NCBITaxon_33317 obo:NCBITaxon_2759 obo:NCBITaxon_6072 obo:NCBITaxon_6960 obo:NCBITaxon_33208 obo:NCBITaxon_41196 obo:NCBITaxon_197562 obo:NCBITaxon_85512 obo:NCBITaxon_197563 obo:NCBITaxon_95182 obo:NCBITaxon_41197 obo:NCBITaxon_6656 obo:NCBITaxon_7496 obo:NCBITaxon_7088 obo:NCBITaxon_1206794 obo:NCBITaxon_88770 obo:NCBITaxon_7100 obo:NCBITaxon_33392 obo:NCBITaxon_50557'><span id='am-42' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-43' property="rdfs:label" content="Data" datatype="xsd:string"></span><span id='am-44' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-45'  ></span>data</span> of <br />                                 published experiments performed new experiments modification E2F expression cell <br />                                 lines, reporter assays chromatin immunoprecipitation. Ectopic expression endogenous <br />                                 activation E2F induced expression SIL, knockdown E2F shRNA, downregulated <br />                                 SIL expression. E2F activated SIL promoter reporter assay bound SIL promoter in-vivo. <br />                                 Taken data demonstrate SIL regulated E2F. As SIL essential mitotic <br />                                 entry, E2F regulate G2/M transition induction SIL. Furthermore, silencing of <br />                                 SIL cause apoptosis cancer cells, finding therapeutic relevance tumors with <br />                                 constitutive activation E2F. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                            Keywords <br />                                 SIL; E2F; Mitosis <br />  <br />                                             The SIL gene, (SCL Interrupting Locus), located chromosome 1, encodes cytosolic protein <br />                                             critical role cell growth proliferation 1&#8201;2&#8201;3. SIL tightly regulated the <br />                                             cell cycle. Its mRNA expression higher rapidly proliferating cells 4 tissues, it <br />                                             decreases rapidly terminal differentiation 5. The SIL protein phopshorylated upon <br />                                             transition mitosis degraded exit mitosis4, 6 SIL necessary mitotic <br />                                             entry proper organization mitotic spindle 3&#8201;7. <br />  <br />  <br />  <br />  <br />                            Corresponding author: Shai Izraeli, Dpt. Pediatric Hemato-Oncology, Sheba Medical Center, Tel- Hashomer 52621 Israel. E-mail: <br />                            sizraeli@sheba.health.gov.il Tel +972-3-5303037 Fax +972-3-5303031. <br />                             Erez et al.                                                                                              Page 2 <br />  <br />  <br />                                            SIL critical role cell growth proliferation lead examine role tumorgenesis. <br />                                            Increased expression SIL observed multiple types cancer associated with <br />                                            metastatic spread8. SIL essential cancer cells survival knockdown SIL resulted in <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            marked delay mitotic entry coupled apoptosis, in-vitro in-vivo 3. SIL expression <br />                                            tumors correlates significantly expression pattern mitotic spindle <br />                                            checkpoint genes with, high histopathological mitotic index. We interested in <br />                                            elucidating transcriptional basis co-regulation SIL expression other <br />                                            mitotic spindle checkpoint genes. <br />  <br />                                            Numerous studies shown E2F <span id='am-11' about='obo:NCBITaxon_family' typeof='owl:Thing NCBITaxon:_taxonomic_rank'><span id='am-12' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-13' property="rdfs:label" content="family" datatype="xsd:string"></span>family</span> proteins aberrantly activated multiple <br />                                            cancers. The E2F transcription factors demonstrated control gene expression <br />                                            necessary cell cycle progression, particularly G1/S transition. Recently role for <br />                                            E2F regulating mitosis emerged. Specifically, E2F1 shown induce the <br />                                            transcription genes coding mitotic checkpoint regulator proteins, MAD2. As SIL <br />                                            expression highly correlated expression MAD2, 3&#8201;8, hypothesized SIL <br />                                            target E2F. <br />  <br />                                Materials Methods <br />                                SIL regulation E2F induction <br />                                            WI38 human embryonic lung fibroblasts stably expressing E2F1 fused ligand binding <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            domain estrogen receptor induced E2F1 activation 4-hydroxytamoxifen <br />                                            (OHT) (300 nM) published 9. <br />  <br />                                            PCR&#8212;In 50 &#181;L PCR reaction; 50&#8211;100 ng DNA sample, 15 pmol 5&apos; 3&apos; <br />                                            oligonucleotide primers, 1.5 U Super-Therm DNA polymerase used. Conditions: <br />                                            initial denaturation 5 minutes 95&#176;C, followed 35 cycles 60 seconds 95&#176;C, 60 <br />                                            seconds 58&#176;C, 90 seconds 72&#176;C using MJ Research PTC-100 thermal cycler. After <br />                                            cycle, additional extension step 10 minutes 72&#176;C performed. Appropriate <br />                                            positive negative controls included experiments <br />  <br />                                            The oligonucleotides used amplification: <br />  <br />                                            Hu-SIL&#8212;F- 5&apos;&#8211;GACTACTTCAGGCACAGATTC-3&apos; R- 5&apos; &#8211; <br />                                            ATGCATGCCAACACACTG-3&apos; <br />  <br />                                            Cell culture: Drosophilla melangogaster SL2 cells (obtained A.Black) cultured at <br />                                            room temperature Schneider&#8217;s Drosophila medium (Life Technologies) supplemented with <br />                                            10% fetal calf serum (Rehatuin Intergen). 293T cell line grown DMEM supplemented <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            10% heatinactivated fetal bovine serum, penicillin&#8211;streptomycin (100U 100 mcg/ml, <br />                                            respectively) 2mM glutamine (Life Technologies). WI38 human embryonic lung <br />                                            fibroblasts published 9. <br />  <br />                                            Infection shRNA E2F1&#8212;293T cell line transfected shRNA E2F1 <br />                                            (5&#8217; GACGTGTCAGGACCTTCGT) 9. pSuper reterovirus plasmid gag <br />                                            pole Maloni virus, The viral supernated harvested 48 hours later, filtered through <br />                                            0.45 micron mixed u 8 mcg/ml polybrene added T-Cell leukemic cell- line, plated <br />                                            day 6 plate concentration 2&#215; 10 5. The cells centrifuged 45 <br />                                            minutes, 1800 RPM room temperature. The procedure repeated 24 hours later. The <br />                                            infected cells selected Puromycin 10 mcg/ml 10 days extraction of <br />                                            RNA. <br />  <br />  <br />  <br />  <br />                                                 Int J Cancer. Author manuscript; available PMC 2009 October 1. <br />                             Erez et al.                                                                                                Page 3 <br />  <br />  <br />                                Reporter Assay <br />                                            <span id='am-46' about='obo:NCBITaxon_36549' typeof='owl:Thing obo:NCBITaxon_1 obo:NCBITaxon_28384'><span id='am-47' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-48' property="rdfs:label" content="plasmids" datatype="xsd:string"></span><span id='am-49' property="oboInOwl:hasDbXref" content="GC_ID:11" datatype="xsd:string"></span><span id='am-50' property="oboInOwl:hasAlternativeId" content="NCBITaxon:2435" datatype="xsd:string"></span>Plasmids</span>&#8212;a 2.3 kb fragment encompassing SIL transcription initiation site was <br />                                            subcloned Xba I site chloramphenicol acyltransferase (CAT) reporter plasmid, <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            p CAT Basic (Promega) generate pCATSIL. PMINCATSIL prepared exonuclease <br />                                            III digestion. <br />  <br />                                            Transfection SL2 Cells&#8212;SL2 cells transected calcium- phosphate <br />                                            coprecipitation mcg DNA plasmid (with exception E2F1- O.2 <br />                                            mcg). A truncated adenovirus 10 cotransfected control transfection efficiency. The <br />                                            total transfected DNA adjusted 20 mcg pBLUESCRIPT II. Cells were <br />                                            harvested 2 days, pelleted 1000 &#215; g resuspended Reporter Lysis Buffer <br />                                            (Promega). The lysates analyzed according protocol. All CAT data normalized <br />                                            luciferase activity control transfection efficiency. The fold activation calculated <br />                                            based pCAT Basic expression. <br />  <br />                                Chromatin immunoprecipitation <br />                                            performed described 9 The PCR preformed using oligos: <br />  <br />                                SIL promoter <br />                                            F- 5&apos;- CCGCAGTTCTCCAAGAAGAC- 3&apos; R-5&apos;GAACTGAGGCGGCAAAC- 3&apos; <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                Exon 12 SIL <br />                                            F- 5&#8217;GAGACACTGCAAAGTAAGACAG3&#8217; R-5&#8217;GTGGAGGGTCTTATAGGATACTC3&#8217; <br />  <br />                                Results <br />                                Bioinformatic analysis published data suggests SIL E2F target gene <br />                                            The finding MAD2, characterized mitotic check point gene co-expressed with <br />                                            SIL cancer cells, target E2F1 11 lead hypothesize SIL E2F1 <br />                                            target gene. We interrogated raw microarray data studies human <br />                                            mice cell lines, designed E2F1 direct target genes 12&#8201;13&#8201;14. We either <br />                                            ectopic overexpression E2F1 silencing Rb gene cell lines, result rise <br />                                            mouse human SIL, known E2F1 target genes. Table 1 <br />                                            summarizes results Semizarov paper focusing E2F induced mitotic genes human <br />                                            cell lines SIL results retrieved supplementary data (table 1)&#8201;13. <br />                                            Thus, mining publicly available data reveals SIL induced similar pattern of <br />                                            response known E2F1 induced genes necessary insure proper G2/M transition. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                SIL induced E2F vitro <br />                                            To examine SIL induced activation E2F utilized previously published <br />                                            human WI-38, embryonic lung fibroblasts engineered conditionally express E2F1 after <br />                                            treatment 4-hydroxytamoxifen (OHT) 9. Activation E2F OHT associated with <br />                                            increased mRNA levels SIL (Figure 1A). As alternative ectopic expression E2F we <br />                                            wished examine effect activation endogenous E2F1 SIL. E1A viral <br />                                            oncoprotein that, expressed, binds inhibits Rb consequently activates the <br />                                            endogenous E2Fs. As previously shown, SIL expressed serum starved growth <br />                                            arrested fibroblasts (Figure 1B, lane 1). Transfection E1A resulted marked expression of <br />                                            SIL mRNA, despite serum starvation (Figure 1B, lane 2). Similarly expression SIL <br />                                            markedly increased proliferating fibroblasts activation endogenous E2F1 E1A <br />                                            (Figure 1B, lane 4 comparison lane 3). To substantiate relationship between <br />                                            E2F1 SIL infected T- cell leukemic cell line shRNA E2F1 a <br />  <br />                                                 Int J Cancer. Author manuscript; available PMC 2009 October 1. <br />                             Erez et al.                                                                                               Page 4 <br />  <br />  <br />                                            nonspecific shRNA. As seen Figure 1C knockdown E2F associated with <br />                                            reduction SIL expression. Taken together, results suggest expression SIL is <br />                                            regulated E2F1. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                E2F binding sites SIL promoter functional vitro vivo <br />                                            We wanted examine E2F induce SIL expression directly activation and <br />                                            binding promoter. SIL promoter 15 potential E2F1 binding sites region <br />                                            conserved human mouse &#8722;162 &#8722;26 transcription initiation site. <br />                                            The upstream site 6/8 match murine sequence downstream site well <br />                                            conserved. However, binding site 7/8 match E2F binding site N-MYC. 16. <br />  <br />                                            To determine binding sites functionally active SIL promoter, performed <br />                                            reporter assay using SIL promoter, pCATSIL, deleted construct possessing <br />                                            &#8722;80 nucleotide start transcription initiation site, pMINCATSIL (Figure 2A). <br />                                            Only E2F site positioned SIL minimal promoter vector. To determine whether <br />                                            E2F modulate SIL promoter activity transfected pCATSIL PMINCATSIL <br />                                            D. melangaster SL2 cells E2F1 coexpression vector. The SIL <span id='am-30' about='obo:NCBITaxon_29278' typeof='owl:Thing obo:NCBITaxon_81077 obo:NCBITaxon_1 obo:NCBITaxon_28384'><span id='am-31' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-32' property="oboInOwl:hasDbXref" content="GC_ID:11" datatype="xsd:string"></span><span id='am-33' property="rdfs:label" content="vectors" datatype="xsd:string"></span>vectors</span> <br />                                            low activity SL2 cells absence E2F. After correcting fold <br />                                            activation promotorless construct, pCATBasic, coexpression E2F1 pCATSIL <br />                                            resulted 6-fold increased activation coexpression E2F1 pMINCATSIL lead <br />                                            12-fold increased CAT activity (Figure 2B). <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            To examine E2F transcription factors bound SIL promoter in-vivo performed <br />                                            chromatin immunoprecipitation assay (ChIp). Chromatin Jurkat cells (human T <br />                                            lymphocyte cell line) crosslinked immunoprecipitated antibodies E2F1, E2F2, <br />                                            E2F3, E2F4, HA used template PCR amplification SIL. Negative (no DNA) <br />                                            positive (input DNA representing 0.2% total input chromatin) control amplifications <br />                                            shown (Figure 2C). SIL primers constructed promoter containing E2F1 <br />                                            binding site, exon 12, containing E2F1 binding site (negative control). <br />                                            All E2F factors, particular E2F1 E2F4 bound SIL promoter. The <br />                                            results E2F binding sites SIL promoter functional vitro in-vivo, <br />                                            especially E2F1 E2F4. <br />  <br />                                Discussion <br />                                            The E2F transcription factors aberrantly activated cancer. Recent studies revealed <br />                                            expanded role E2F cell cycle regulation function regulating G1 S <br />                                            transition suggest plays role regulating G2/M transition 17.18. Specifically it <br />                                            shown regulate MAD2 spindle checkpoint gene. MAD2 essential <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            component spindle checkpoint blocks premature sister chromatid separation during <br />                                            metaphase. E2F1 activation MAD2 expression shown critically important <br />                                            cancer phenotype. We recently shown SIL overexpressed large variety <br />                                            cancers expression essential mitotic entry cell survival 3&#8201;8. SIL <br />                                            expression highly correlated expression mitotic checkpoint genes, as <br />                                            MAD2. Here confirmed hypothesis E2F regulates expression SIL. <br />  <br />                                            Analysis raw databases published micro-array experiments revealed SIL a <br />                                            target gene E2F1 genes upregulated G2/M phase cell <br />                                            cycle 12&#8201;13&#8201;14&#8201;8. We experimentally demonstrated SIL regulated E2F1 that <br />                                            E2F1 E2F4 bind SIL promoter. <br />  <br />                                            Although SIL general role growth development observed mouse zebra <br />                                            fish mutants 2, 19, function unknown. We recently shown SIL an <br />  <br />  <br />                                                 Int J Cancer. Author manuscript; available PMC 2009 October 1. <br />                             Erez et al.                                                                                                                 Page 5 <br />  <br />  <br />                                          important mitotic regulator 3&#8201;6. It phosphorylated mitosis degraded upon <br />                                          transition G1. Silencing SIL demonstrated needed mitotic entry activation <br />                                          CDK1/Cyclin B complex. A recent study Pfaff et al,7 demonstrated SIL localizes <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                          mitotic spindle poles metaphases essential proper organization the <br />                                          mitotic spindle. Together studies establish SIL major mitotic regulator. <br />  <br />                                          SIL second mitotic regulator, MAD2, unequivocally shown be <br />                                          regulated E2F1. Co-regulation S phase genes G2/M genes transcription <br />                                          factor ensures proper coordination DNA replication preparation mitosis. <br />                                          Accordingly, deregulation activity cancer leads enhanced DNA replication and <br />                                          defects mitotic checkpoint. SIL regulation E2F1 implications many <br />                                          types cancers, cancers display aberrant expression E2F pathway. Since <br />                                          SIL required survival cancer cells 3, drugs targeting E2F1 mediate anticancer <br />                                          activity silencing SIL. More specifically, T-Cell-ALL SIL promoter causes <br />                                          aberrant expression oncogenic SCL, blockage E2F1 reverse leukemia by <br />                                          counteracting activity SIL promoter. <br />  <br />                                Supplementary Material <br />                                          Refer Web version PubMed Central supplementary material. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                Acknowledgments <br />                                          Source Support- <span id='am-19' about='obo:NCBITaxon_169495' typeof='owl:Thing obo:NCBITaxon_33340 obo:NCBITaxon_33213 obo:NCBITaxon_169440 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_7147 obo:NCBITaxon_43733 obo:NCBITaxon_33154 obo:NCBITaxon_43738 obo:NCBITaxon_480117 obo:NCBITaxon_33317 obo:NCBITaxon_169449 obo:NCBITaxon_480118 obo:NCBITaxon_2759 obo:NCBITaxon_6072 obo:NCBITaxon_6960 obo:NCBITaxon_43750 obo:NCBITaxon_33208 obo:NCBITaxon_85512 obo:NCBITaxon_197562 obo:NCBITaxon_197563 obo:NCBITaxon_7203 obo:NCBITaxon_6656 obo:NCBITaxon_7496 obo:NCBITaxon_1206794 obo:NCBITaxon_88770 obo:NCBITaxon_33392 obo:NCBITaxon_169455 obo:NCBITaxon_50557 obo:NCBITaxon_43741'><span id='am-20' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-21' property="rdfs:label" content="This" datatype="xsd:string"></span><span id='am-22'  ></span><span id='am-23' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span>This</span> study supported research grants Israel Science Foundation, Israel Cancer <br />                                          Research Foundation, US-Israel Binational Science Foundation Intramural Research Program NIH, <br />                                          NCI <br />  <br />                                          This work preformed partial fulfillment requirements PhD degree Ayelet Erez, Sackler Faculty <br />                                          Medicine, Tel-Aviv University <br />  <br />  <br />                                Bibliography <br />                                          1. Aplan PDLD, Ginsberg AM, Cossman J, Bertness VL, Kirsch IR. Disruption human SCL locus <br />                                             &quot;illegitimate&quot; V-(D)-J recombinase activity. SCIENCE 1990;250(4986):1426&#8211;1429. [PubMed: <br />                                             2255914] <br />                                          2. Izraeli S, Lowe LA, Bertness VL, Good DJ, Dorward DW, Kirsch IR, et al. The SIL gene required <br />                                             mouse embryonic axial development left- right specification. Nature 1999;399(6737):691&#8211; <br />                                             694. [PubMed: 10385121] <br />                                          3. Erez A, Castiel A, Trakhtenbrot L, Perelman M, Rosenthal E, Goldstein I, et al. The SIL gene essential <br />                                             mitotic entry survival cancer cells. Cancer Res 2007;67(9):4022&#8211;4027. [PubMed: 17456584] <br />                                          4. Izraeli S, Colaizzo-Anas T, Bertness VL, Mani K, Aplan PD, Kirsch IR. Expression SIL gene <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             correlated growth induction cellular proliferation. Cell Growth Differ 1997;8(11):1171&#8211; <br />                                             1179. [PubMed: 9372240] <br />                                          5. Collazo-<span id='am-1' about='obo:NCBITaxon_316718' typeof='owl:Thing obo:NCBITaxon_78536 obo:NCBITaxon_3646 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_3398 obo:NCBITaxon_1437183 obo:NCBITaxon_33090 obo:NCBITaxon_235631 obo:NCBITaxon_3977 obo:NCBITaxon_91827 obo:NCBITaxon_131221 obo:NCBITaxon_71240 obo:NCBITaxon_58024 obo:NCBITaxon_1437201 obo:NCBITaxon_58023 obo:NCBITaxon_91835 obo:NCBITaxon_235892 obo:NCBITaxon_2759 obo:NCBITaxon_35493 obo:NCBITaxon_71275 obo:NCBITaxon_3193'><span id='am-2' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-3' property="rdfs:label" content="Garcia" datatype="xsd:string"></span><span id='am-4' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-5'  ></span>Garcia</span> NSP, Aplan PD. Cloning characterization murine SIL gene. Genomics 1995;30 <br />                                             (3):506&#8211;513. [PubMed: 8825637] <br />                                          6. Campaner SKP, Izraeli S, Kirsch IR. Sil phosphorylation Pin1 binding domain affects duration <br />                                             spindle checkpoint. Mol Cell Biol 2005;25(15):6660&#8211;6672. [PubMed: 16024801] <br />                                          7. Pfaff KL, Straub CT, Chiang K, Bear DM, Zhou Y, Zon LI. The Zebra fish cassiopeia Mutant Reveals <br />                                             SIL Is Required Mitotic Spindle Organization. Mol Cell Biol 2007;27(16):5887&#8211;5897. <br />                                             [PubMed: 17576815] <br />                                          8. Erez APM, Hewitt SM, Cojacaru G, Goldberg I, Shahar I, Yaron P, Muler I, Campaner S, Amariglio <br />                                             N, Rechavi G, Kirsch IR, Krupsky M, Kaminski N, Izraeli S. Sil overexpression lung cancer <br />                                             characterizes tumors increased mitotic activity. Oncogene 2004;23(31):5371&#8211;5377. [PubMed: <br />                                             15107824] <br />  <br />  <br />  <br />                                                Int J Cancer. Author manuscript; available PMC 2009 October 1. <br />                             Erez et al.                                                                                                      Page 6 <br />  <br />  <br />                                          9. Chaussepied M, Ginsberg D. Transcriptional regulation AKT activation E2F. Mol Cell  <br /> </body></html>